A key tariff exemption considers a drug's origin to be where its Active Pharmaceutical Ingredient (API) was made. This allows companies to manufacture an API in the US, export it for final formulation, and then re-import the finished product tariff-free, offering a significant supply chain strategy to bypass import taxes.

Effective tariff reduction requires a deep dive into three fundamental customs compliance areas: country of origin rules, correct tariff code classification, and customs valuation methods. Experts suggest the biggest savings opportunities for many firms lie in scrutinizing and optimizing these often-overlooked details to legitimately lower their dutiable base.

Flexport CEO Ryan Peterson reveals that high tariffs incentivize foreign companies to under-declare goods' value. The U.S. uniquely allows imports without a local entity, meaning there's little recourse when fraud is discovered. This creates a significant competitive disadvantage for American companies that follow the rules.

Experts predicted air freight prices would plummet after the U.S. ended the duty-free 'de minimis' rule for China. Instead, prices remained high because a massive, simultaneous boom in shipping components for AI data centers absorbed all the excess capacity.

The success of tariffs hinges on the insight that China's economic model prioritizes volume and employment over per-unit profitability. This creates a vulnerability where Chinese producers are forced to absorb tariff costs to maintain output, effectively subsidizing the tariff revenue and preventing significant price increases for US consumers.

While large firms like NVIDIA can onshore manufacturing, small hardware startups relying on Chinese production are the primary casualties of tariffs. They lack the scale to move supply chains or secure exemptions, eroding their margins and weakening their negotiating position with investors.

By ensuring over 90% of its Brazilian GMV comes from local sellers, Shopee built a significant defense against protectionist policies. This insulates them from regulations targeting foreign imports, a risk faced by competitors like Temu and AliExpress.

If tariffs are reduced following a court ruling, companies will experience immediate cost relief. However, these savings are passed to consumers slowly, over two to three quarters. This delay creates a temporary tailwind for corporate profit margins before prices on the shelf fall.

Unlike large firms making US investment pledges for exemptions, smaller drug makers must rely on nuanced, capital-light tactics. These include unbundling costs to lower dutiable value, using duty drawback programs for re-exported goods, and leveraging foreign trade zones to survive high tariff rates without massive infrastructure spending.